Ideaya Biosciences (IDYA) financial statements
Ideaya Biosciences reported revenue of $219M in fiscal 2025, up 62.1% a year over 5 years.
Net income was -$114M.
Free cash flow was -$73M.
The diluted share count rose 12625% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Ideaya Biosciences's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $20M | $28M | $51M | $23M | $7M | $219M |
| Research and development | $12M | $32M | $34M | $40M | $58M | $90M | $130M | $295M | $315M |
| Selling, general and admin | $2M | $5M | $10M | $15M | $20M | $24M | $28M | $39M | $63M |
| Operating income | -$14M | -$36M | -$44M | -$35M | -$50M | -$63M | -$134M | -$327M | -$159M |
| Income tax | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12M | -$34M | -$42M | -$34M | -$50M | -$59M | -$113M | -$274M | -$114M |
| EPS (diluted) | -$17.06 | -$35.92 | -$3.36 | -$1.40 | -$1.41 | -$1.42 | -$1.96 | -$3.36 | -$1.28 |
| Diluted shares | 1M | 1M | 12M | 25M | 35M | 41M | 58M | 82M | 88M |
| Operating margin | — | — | — | -180.9% | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% |
| Net margin | — | — | — | -176.6% | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
Balance sheet
Fiscal years, from Ideaya Biosciences's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $6M | $90M | $99M | $284M | $247M | $365M | $525M | $676M | $639M |
| Receivables | — | — | — | $2M | $1M | $211,000 | $18,000 | $3,000 | — |
| Total current assets | — | $91M | $102M | $289M | $251M | $370M | $533M | $690M | $667M |
| Property, plant and equipment | — | $5M | $5M | $4M | $5M | $7M | $6M | $9M | $8M |
| Total assets | — | $97M | $113M | $298M | $381M | $388M | $649M | $1.1B | $1.1B |
| Total current liabilities | — | $5M | $7M | $39M | $45M | $32M | $27M | $46M | $59M |
| Total liabilities | — | $7M | $13M | $100M | $80M | $39M | $28M | $65M | $86M |
| Shareholders' equity | -$16M | -$49M | $100M | $198M | $302M | $349M | $621M | $1.1B | $1.0B |
| Net debt | -$6M | -$21M | -$34M | -$72M | -$92M | -$69M | -$157M | -$84M | -$113M |
Cash flow
Fiscal years, from Ideaya Biosciences's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12M | -$28M | -$39M | $55M | -$56M | -$87M | -$115M | -$248M | -$71M |
| Capital spending | $2M | $2M | $1M | $493,000 | $3M | $3M | $2M | $4M | $2M |
| Free cash flow | -$14M | -$29M | -$41M | $55M | -$58M | -$91M | -$118M | -$251M | -$73M |
| Stock-based compensation | $136,000 | $950,000 | $2M | $4M | $8M | $12M | $18M | $35M | $46M |
| Free cash flow margin | — | — | — | 281.3% | -209.1% | -177.9% | -502.9% | -3592.0% | -33.6% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IDYA.
Open IDYA in InvestinglyQuestions
What was Ideaya Biosciences's revenue in 2025?
$219M in fiscal 2025, from its 10-K filing.
How much free cash flow does Ideaya Biosciences generate?
-$73M in fiscal 2025 (operating cash flow minus capital spending).
From Ideaya Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.